GLP-1 peptides, FDA-approved for type-2 diabetes (e.g., Semaglutide and Exenatide) and weight loss (Semaglutide) have been studied for their effects on alcohol use in both preclinical and clinical studies (for a detailed review: 10). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.